CoChat

Safety and Efficacy of AlphaWave® l-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Moulin, Marc, Crowley, David C., Xiong, Lora, Guthrie, Najla, Lewis, Erin D. · 2024 · Neurology and Therapy

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 6 of the 38 sources its claims cite were checked for support.

Abstract

Prolonged periods of stress may lead to negative health consequences. AlphaWave ® l -Theanine was safe and efficacious during an acute stress challenge. However, double-blind, placebo-controlled clinical trials investigating the longer term effects of l -theanine supplementation on stress are warranted. Thirty healthy adults (18–65 years) with moderate stress were randomized to AlphaWave ® l -Theanine (400 mg l -theanine/day) or placebo ( n = 15/group) for 28 days. Stress was assessed by salivary cortisol, Perceived Stress Scale (PSS) and Depression, Anxiety and Stress Scale-21; sleep was assessed by the Healthy People Sleep Quality Index and actigraphy device; cognition was assessed by Computerized Mental Performance Assessment System; mood was assessed by Profile of Mood States. All outcomes were measured at baseline, Days 14 and 28. Safety included vital signs, clinical chemistry, haematology and adverse events (AEs). All AEs were resolved by the end of the study period or upon subsequent follow up, and out of range laboratory values and changes in vital signs were deemed not clinically relevant following AlphaWave ® l -Theanine supplementation. Participants supplemented with AlphaWave ® l -Theanine had decreases of 12.92% ( p = 0.051) and 17.98% ( p = 0.04) in PSS scores after 14 and 28 days, respectively, while those on placebo had respective decreases of 9.74% ( p = 0.061) and 17.88% ( p = 0.009). There were no significant differences between groups for change in salivary cortisol. The AlphaWave ® l -Theanine group demonstrated decreased time asleep after 28 days and significantly reduced light sleep after 14 and 28 days compared to placebo ( p ≤ 0.040). The AlphaWave ® l -Theanine group significantly improved by 21.79% and 21.33% in Stroop test correct reaction time after 14 and 28 days, respectively, while those on placebo improved after 28 days only ( p = 0.005). AlphaWave ® l -Theanine supplementation for 28 days was safe and significantly decreased perceived stress significantly decreased perceived stress and light sleep, improved sleep quality and enhanced cognitive attention in the studied population. Larger, randomized controlled trials with longer duration of AlphaWave ® l -Theanine supplementation are warranted to reduce inter-individual variability and the potential placebo effect. ClinicalTrials.gov identifier, NCT05808595.

Overview

CoChat Summary

TL;DR

In a 28-day randomized, double-blind, placebo-controlled trial in 30 healthy adults with moderate stress, AlphaWave® l-theanine (400 mg/day) was safe and well tolerated. It significantly reduced PSS scores from baseline and light sleep versus placebo and improved Stroop correct reaction time from baseline, but there were no significant between-group differences for PSS or salivary cortisol, and placebo also improved on several measures.

Key findings

  • Safety: 9 adverse events (AEs) were reported by 6 participants; 8 AEs occurred in 5 AlphaWave® l-theanine participants and 1 in a placebo participant. Two AlphaWave® AEs (metallic taste, dry mouth) were mild and possibly related; all AEs resolved, and no clinically relevant vital sign or laboratory changes were found.
  • Perceived stress: AlphaWave® l-theanine decreased PSS scores from baseline at Day 14 (p = 0.051) and Day 28 (p = 0.04); placebo decreased at Day 14 (p = 0.061) and Day 28 (p = 0.009). There were no significant between-group differences, and no significant between-group differences in salivary cortisol.
  • Sleep: AlphaWave® l-theanine showed decreased time asleep at Day 28 versus placebo (change −29.62 ± 51.77 vs. +18.11 ± 63.29 min; p = 0.032) and reduced light sleep at Days 14 and 28 versus placebo (p = 0.040 and p = 0.026). No significant between-group differences were found for HPSQI subjective sleep data.
  • Cognition/mood: AlphaWave® l-theanine improved Stroop correct reaction time from baseline at Day 14 (p = 0.037) and Day 28 (p = 0.013); placebo improved at Day 28 only (p = 0.005), with no significant between-group RT differences. DASS-21 total and stress subscale scores decreased more in placebo at Day 28 (p = 0.017 and p = 0.012), and there were no significant between-group POMS differences.

Methods

  • Randomized, double-blind, placebo-controlled, parallel trial with a 7-day run-in and 28-day supplementation period; 30 healthy adults aged 18–65 with moderate stress (PSS 14–26) were randomized n = 15/group to AlphaWave® l-theanine 400 mg/day (200 mg twice daily) or placebo.
  • Primary outcome was salivary cortisol; secondary outcomes included PSS, DASS-21, Healthy People Sleep Quality Index, actigraphy, COMPASS cognition, and POMS mood at baseline, Days 14 and 28; safety included AEs, vital signs, clinical chemistry, and haematology.
  • Analyses used the intention-to-treat/safety population in R 4.2.1; between-group differences used two-sample t-test, Wilcoxon rank sum, or Fisher’s exact test, and within-group differences used paired t-test or Wilcoxon signed rank test, with p ≤ 0.05 considered significant.

Limitations

  • Stated: the sample was primarily female, limiting generalizability; larger samples and longer trials are needed to reduce inter-individual variability and assess whether the placebo effect wanes; salivary cortisol may be confounded by sampling timing, light exposure, sleep changes, or prior-day stress; PSS and DASS-21 findings conflicted.
  • Evident: baseline imbalances existed between groups (morning salivary cortisol higher in placebo, p = 0.028; time asleep higher in AlphaWave® l-theanine, p = 0.049; Stroop accuracy differences at baseline, p = 0.039), which may complicate interpretation of between-group changes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40120-024-00624-7

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Study design
Fig. 1 Study designCC BY-NC · PubMed Central
Fig. 2 Disposition of study participants. ITT intention to treat
Fig. 2 Disposition of study participants. ITT intention to treatCC BY-NC · PubMed Central
Fig. 3 Change in Perceived Stress Scale score from baseline at Days 14 and 28. *Significant within-group difference in PSS score from baseline (p < 0.05). PSS perceived stress scale
Fig. 3 Change in Perceived Stress Scale score from baseline at Days 14 and 28. *Significant within-group difference in PSS score from baseline (p < 0.05). PSS perceived stress scaleCC BY-NC · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 26 Not checked · 82 Own results and interpretations

53 more claims

Create a free account to see all 114 claims and to verify the 32 references still open.

See all claims — free account
  • Probably not a substantial claim. 38
  • It may state two separate claims as one. 30

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 14

Metadata

Authors
Moulin, M., Crowley, D. C., Xiong, L., Guthrie, N., & Lewis, E. D.
Corresponding author
Lewis, Erin D.
Venue
Neurology and Therapy
Published
2024-05-17
Volume
13
Issue
4
Pages
1135-1153
ISSN
  • 2193-6536 (ISSN-L)
  • 2193-8253
OpenAlex
W4397006913
Cited by
14
References
26
Citations by year
2026: 9 · 2025: 4 · 2024: 1
FWCI
7.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Neurology and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Ethical Naturals, Inc.
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Bioactive Compounds
Keywords
theanine, dietary supplementation, acute stress, perceived stress, salivary cortisol, sleep quality, light sleep, cognitive performance, Stroop task, mood, adverse events, safety, healthy adults, actigraphy, Profile of Mood States, DASS-21, PSS, cognitive flexibility, reaction time

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of AlphaWave® l-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1007/s40120-024-00624-7
The paper
Moulin, M., Crowley, D. C., Xiong, L., Guthrie, N., & Lewis, E. D. (2024). Safety and Efficacy of AlphaWave® l-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurology and Therapy. https://doi.org/10.1007/s40120-024-00624-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.